Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443003 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3182791 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31395676 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3177549 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15500293 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL313703 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16329524 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL39999 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16329522 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL21479469 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563586-A1 | NEW INHIBITORS OF LRRK2/PP1 INTERACTION | Université Paris Cité (FR) | 2025-06-04 | — | — | EP | claimed |
| US-20260110690-A1 | PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES | REGENERON PHARMACEUTICALS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | YUAN YU (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12540945-B2 | Probe and method for identifying host cell protein impurities | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250362432-A1 | OPHTHALMIC DEVICES CONTAINING PHOTOSTABLE MIMICS OF MACULAR PIGMENT AND OTHER VISIBLE LIGHT FILTERS | JOHNSON & JOHNSON VISION CARE (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090137773-A1 | Production Processes and Systems, Compositions, Surfactants, Monomer Units, Metal Complexes, Phosphate Esters, Glycols, Aqueous Film Forming Foams, and Foam Stabilizers | ASEPSIS, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1957644-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2008-08-20 | — | — | EP | disclosed |
| EP-1907343-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007016359-A2 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | GREAT LAKES CHEMICAL CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| CN-1333746-A | Molecular scaffold useful as a template comprising urethane linkages | JOLLA PHARMA (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-0292128-A1 | Improved DNA probes | TAMIR BIOTECHNOLOGY LTD (IL) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885 |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | MEN1 3861/4885KMT2A 1082/4885TSHR 3837/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | MEN1 2996/4885KMT2A 4351/4885TSHR 437/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | MEN1 2993/4885KMT2A 4631/4885TSHR 204/4885 |
| US-20090137773-A1 | Production Processes and Systems, Compositions, Surfactants, Monomer Units, Metal Complexes, Phosphate Esters, Glycols, Aqueous Film Forming Foams, and Foam Stabilizers | RFC3, RFC2, RFC4 | MEN1 3736/4885KMT2A 2670/4885TSHR 2661/4885 |
| US-20260110690-A1 | PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES | BTD, LIPC, LPL | MEN1 4868/4885KMT2A 3874/4885TSHR 1144/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | MEN1 4667/4885KMT2A 2494/4885TSHR 2615/4885 |
| US-12540945-B2 | Probe and method for identifying host cell protein impurities | BTD, LPL, LYPLA2 | MEN1 4860/4885KMT2A 3985/4885TSHR 1331/4885 |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | SOS1, KRAS, SOS2 | MEN1 815/4885KMT2A 1078/4885TSHR 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.